Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer’s treatment Leqembi that may ultimately help bolster uptake of the drug.
Weekly treatment with an experimental subcutaneous formulation of Leqembi, which could be easier to administer than the currently approved biweekly intravenous version, resulted in 14% greater amyloid-plaque removal than the IV treatment after six months, the companies said in a release. Amyloid plaques, a hallmark of Alzheimer’s disease, are protein clumps that can accumulate…
Read the full article here